Introduction

Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome originally described in 1906. Classically, this condition is characterized by nail dystrophy, abnormal skin pigmentation, and oral leukoplakia. Inheritance is most often x-linked recessive and DC results from gene mutations that impair telomerase function. Thus, patients have shorter telomeres than expected. DC is more commonly seen in males, but in total only 552 cases were recorded over the span of 30 years. There is heterogeneity at both the genetic and clinical presentation levels, and other syndromes in this family of bone marrow failure syndromes includes Fanconi anemia and aplastic anemia. Patients with DC are at higher risk of developing hematological disorders and solid malignancies, the most common of the solid tumors being squamous cell carcinomas (SCCs) of the head and neck, followed by skin and anorectal cancers. The rate of malignancy amongst these patients has been estimated at around 10%.

We present a unique case of a patient with DC who underwent mandibulectomy and free tissue transfer for mandible SCC followed by additional treatments for positive margins and discuss a systematic review on therapeutic management for this patient population.
Methods

Our institution’s Clinical Ethics Review Board provided a routine exemption for this case report.

Case Presentation

A 39-year-old male, diagnosed with dyskeratosis congenita a decade prior, originally presented to his dentist with right facial swelling. Computed tomography showed extensive bony destruction of the right mandible (Figure 1). The patient underwent bony debridement, removal of teeth 44 to 48 (FDI notation), and sampling of the gingiva and tongue by Oromaxillofacial Surgery.

His biopsy results demonstrated moderately-differentiated invasive SCC of the mandible and moderate dysplasia of the right anterior tongue. The patient was referred to Otolaryngology. In consultation, the patient had the typical triad associated with DC. His history and physical examination were otherwise insignificant, with no significant alcohol use or smoking history. The patient was counseled regarding management options for a cT4aN0 oral cavity SCC. Radiation oncology reviewed his case, and all involved reached consensus that surgery would be pursued as first-line treatment. Concerns from our radiation oncologists included worsening acute skin toxicity, long term fibrosis, and esophageal strictures or fistulas.

The patient underwent a right mandibulectomy, selective right neck dissection, and reconstruction with a left osteocutaneous fibular free flap (Figure 1). Pre-planned surgical cutting guides were used, as is standard at our institution (Figure 2). Intraoperative frozen soft tissue margins were not taken as it was felt that the margins were adequate. The fibula was crafted into a 2-segment reconstruction. The patient did well on the ward and was discharged with no complications.

The patient was subsequently seen in follow-up where he was informed that his anterior soft tissue and bony

Figure 1. Axial and coronal CTs of the patient’s mandible at: (a and d) diagnosis, (b and e) initial post-operative, and (c and f) revision post-operative. (g) Mandibular asymmetry before initial resection with characteristic skin pigmentation. (h) Primary mandibulectomy. (i) Revision mandibulectomy.
margin, as well as posterior bony margin, were extensively positive for SCC. This was after bone decalcification was done by pathology, as the bony margins had originally been reported as negative. The patient elected to proceed with a revision mandibulectomy and reconstruction. Margins were extended by an additional 3.5 cm anteriorly and 2.0 cm posteriorly. A 3-segment fibula reconstruction, with the contralateral right fibula as the donor, was performed.

The revision mandibulectomy osteotomy margins were negative for carcinoma and the scant amounts of soft tissue were also negative. However, after discussion with the patient, radiation therapy was added as an additional treatment for the positive soft tissue margins seen with his original mandibulectomy as only small amounts of additional soft tissue were resected with the revision. The patient has since completed his course and does not have recurrence at 6 months from surgery.

**Systematic Review**

The keywords “dyskeratosis congenita” AND “head and neck” OR “otolaryngology” OR “oral cancer” were used to search Medline and Web of Science for case reports between 1980 and 2021. Articles were included that discussed site of primary malignancy, treatment modality, and potential long-term side effects. Exclusion criteria included studies in languages other than English, retracted articles, articles lacking sufficient details, or those that only reported on skin cancers. Bibliographies of included papers were screened for additional studies.

In total, 40 articles were identified in the initial search and 10 others identified through bibliographic screening. Two independent reviewers (AQL, ECD) reviewed abstracts and any discrepancies were resolved by the senior author (JSD). After review, 12 articles satisfied the inclusion criteria. Please refer to Figure 3 for a flow diagram of articles included.

![Figure 2](image-url) 3D-images of patient’s planned fibular reconstruction prior to primary resection (a-c) and revision (d-f). 3D-printed cutting guides during primary resection (g) and revision (h). Revision fibular graft plated to remaining mandible (i).
Results

Included studies’ characteristics are summarized in Table 1. Of the 12 patients, 3 were female and 9 were male (ages 5-41). For initial treatment, 9 patients underwent surgical resection, 1 radiation therapy, 1 chemoradiotherapy, and 1 underwent palliative care. All but 2 patients required multi-modality therapy or revision surgery, and half of (6/12) the patients had recurrence within 1 year of treatment. Follow-up periods varied amongst the cases included, with the longest reported period being 15 months. Examination of those that passed away (5/12) after initial treatment showed a mean survival time of 5.4 months (1-10 months).

Discussion

This case illustrates an important clinical entity for those that provide care for head and neck cancers. We found a total of 12 other case reports of patients with DC and SCC of the head and neck, excluding cutaneous malignancies.5-16 To our knowledge, this is the largest systematic review of this patient population. Of note, most of the cases involved SCC of the tongue; this is the only case that reports on sequential osteocutaneous free tissue transfers.

Our patient did well after both surgical resections and free flap reconstructions with bone and soft tissue transfer, and had no complications. He did unfortunately have extensive positive margins after his first surgery with our team. This was thought to be due to the patient having aggressive disease that was uncharacteristic given his original presentation. We could not find osteocutaneous flaps used in other areas of the body for DC, and it is important to highlight that our patient had no complications with sequential fibular free flap transfers 1-month apart. At the time of follow-up, he was able to do activities of daily living and had minimal functional impact on his lower limbs.

At baseline, DC patients are at high risk for developing bone marrow failure, hence conventional DNA-damaging therapies may accelerate bone marrow failure or cause severe mucositis due to impaired mucosal lining repair.13 Managing these patients should involve discussion with the patients about each treatment option and potential side effects. Patients with DC can have pancytopenia from bone marrow failure, which would also predispose them to complications when considering chemotherapy.5,11 Of the 4 reported patients who underwent radiation therapy, 2 did not tolerate the treatment modality (Refer to Table 1).5,11 One developed severe radiation mucositis after 26 Gy and had to discontinue radiation therapy for surgical resection.5 The other case report details Grade IV mucositis developing after 20 Gy and continued severe mucositis after a treatment break.11 We also do note that our institutions radiation oncologists were hesitant to begin therapy. The decision was made to proceed with radiation as an adjunct after the case was brought up at tumor boards and a long discussion about side effects was had with the patient. Other case reports have also highlighted that oncologists in multi-disciplinary discussions have recommended surgical treatment as first-line due to these concerns.13,15

If malignancy is present, we would also advocate for wide surgical margins for DC patients. It does appear that their cancers are more aggressive based off the other reported cases, as well as our own experience. Routine intraoperative frozen sections may be helpful as their disease seems to more aggressive than clinical presentation would suggest. Only 2 previously reported cases, at the time of writing this manuscript, had not required revision, adjuvant, or salvage treatment modalities.15,16 Furthermore, patients with DC can develop multiple primary malignancies.17,18 Trott et al highlighted the importance of prognosis for these patients, as their patient chose palliative care after diagnosis due to expected quality of life. The average life span for those with DC has been quoted at 23.6 to 42 years.19
This case demonstrates a syndrome that otolaryngologists should be aware of due to patients’ high likelihood of developing malignancy; those with DC have 11-times the risk of being diagnosed with cancer compared to the general population. Estimations of their mean malignant transformation rate of oral leukoplakia has been reported as around 30%. Common oral features of DC include: loss of alveolar bone and buccal mucosa with leukoplakia, extensive dental caries, delayed dental eruption, and gingival inflammation and bleeding. Cannel has discussed that oral tumors in patients with DC often progress from white patches of necrotic epithelium or candida infections to recurrent ulceration and erythroplakia. He proposed that erosive leukoplakia and carcinoma developed at 20 to

Table 1. Summary of Included Studies in Systematic Review of Case Reports, Ordered by Date Published.

| Authors (country) | Patient age and gender | Site of malignancy (stage) | Treatment | Follow-up after original treatment |
|-------------------|------------------------|---------------------------|-----------|-------------------------------------|
| Hyodo et al (Japan) | 24-y-old female | Tongue (T3N1M0) | Radiation therapy (severe side effects) | Recurrence at 6 mo |
| Moretti et al (Italy) | 28-y-old male | Tongue (N/A) | Surgical excision and radiotherapy | Recurrence at 4 mo |
| Cengiz et al (Turkey) | 32-y-old male | Tongue (T3N0M0) | Partial glossectomy and selective neck dissection | N/A |
| Komune et al (Japan) | 31-y-old male | Laryngeal (T4aN0M0) | Total laryngectomy and selective neck dissection | Recurrence at 4 mo |
| Qureishi et al (UK) | 30-y-old male | Posterior pharynx (T2N0) | Transoral laser resection | No recurrence at time of case report writing |
| Bongiorno et al (USA) | 23-y-old female | Tongue (superficially invasive) | Wide local excision | No recurrence at time of case report writing |
| Fatehi et al (India) | 41-y-old male | Tongue | Wide local excision, selective neck dissection, radial forearm free flap | N/A |
| Trott et al (USA) | 10-y-old male | Tongue (T4N2cM0) | Palliative care | Patient passed away 20 d after discharge home |
| Le et al (USA) | 36-y-old male | Maxillary gingiva | Partial maxillectomy, split thickness skin graft, maxillary prosthesis | No recurrence at time of case report writing |
| Ohashi et al (Japan) | 40-y-old male | Buccal mucosa (T4aN1M0) | Chemoradiotherapy as patient refused surgery initially | Recurrence at 5 mo |
| Manfuso et al (Italy) | 38-y-old male | Mandible (T4aN0M0) | Partial mandibulectomy, modified radical neck dissection, fibular free flap | Recurrence at 6 mo |
| Kim and Kim (South Korea) | 5-y-old female | Tongue (T1N0M0) | Partial glossectomy | Recurrence at 3 sites on tongue within 18 mo |

Patient started on immunosuppression and steroids. No recurrence with 15 mo follow-up.
30 years of age, which agrees with the ages of the case reports we found.\textsuperscript{21}

The authors agree that once patients are diagnosed with DC, they should have close follow-up of their upper aero-digestive tract for early detection of malignancies due to a high prevalence of leukoplakia.\textsuperscript{24} While there are a small number of cases found in this review, true incidence is likely much higher. Recommendations for those with DC that have previously been discussed include monthly self-examinations of the oral cavity by patients and annual review with an otolaryngologist.\textsuperscript{4,25} At this time, there is no curative treatment for dyskeratosis congenita.

Conclusion

DC is a syndrome that places patients at higher risk for SCC of the head and neck. Our patient required aggressive revision surgery and adjuvant radiation. It is important for those that practice in the region to understand that recurrence is common and follow-up is needed for this patient population. We would advocate for first-line surgical treatment with wide margins, especially as radiation and chemotherapy may not be well tolerated in those with DC.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Alice Q. Liu https://orcid.org/0000-0003-4813-836X

Ethics Exemption

The University of British Columbia’s Clinical Ethics Review Board provided a routine exemption for this case report.

References

1. Zinsser F. Atrophy, reticular skin pigmentation, dystrophic nails, and oral leukoplakia. Ikonogr Dermat Kioto. 1906;5:219-223.

2. Walne AJ, Marrone A, Dokal I. Dyskeratosis congenita: a disorder of defective telomere maintenance? Int J Hematol. 2005;82(3):184-189. doi:10.1532/IJH97.05067

3. Mason PJ, Bessler M. The genetics of dyskeratosis congenita. Cancer Genet. 2011;204(12):635-645. doi:10.1016/j.cancer-gen.2011.11.002

4. Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in dyskeratosis congenita. Blood. 2009;113(26):6549-6557. doi:10.1182/blood-2008-12-192880

5. Hyodo M, Sadamoto A, Hinohira Y, Yamoto E. Tongue cancer as a complication of dyskeratosis congenita in a woman. Am J Otolaryngol. 1999;20(6):405-407. doi:10.1016/s0196-0709(99)00082-0

6. Fatehi KS, Thiagarajan S, Dhar H, Chaukar D, DCruz AK. Squamous cell carcinoma of the tongue in a patient with dyskeratosis congenita: a rare entity. Br J Oral Maxillofac Surg. 2019;57(1):79-81. doi:10.1016/j.bjoms.2018.12.002

7. Trott KE, Briddell JW, Corao-Uribe D, et al. Dyskeratosis congenita and oral cavity squamous cell carcinoma: report of a case and literature review. J Pediatr Hematol Oncol. 2019;41(6):501-503. doi:10.1097/MPH.0000000000001478

8. Manfuso A, Risitano AM, Copelli M. Dyskeratosis congenita and squamous cell carcinoma of the mandibular alveolar ridge. BMJ Case Rep. 2021;14(5):e242459. doi:10.1136/ber-2021-242459

9. Ohashi N, Iwai T, Ogawa M, Yokoo S, Mitsudo K. Malignant transformation of buccal mucosa leukoplakia in a patient with dyskeratosis congenita. Ear Nose Throat J. 2020;145(6):20398908. doi:10.1177/0145561320938908

10. Moretti S, Spallanzani A, Chiarugi A, Muscarella G, Battini M. Oral carcinoma in a young man: a case of dyskeratosis congenita. J Eur Acad Dermatol Venereol. 2000;14(2):123-125. doi:10.1046/j.1468-3083.2000.00029.x

11. Cengiz M, Celebioglu B, Ozyar E, Lale Atahan I. Unusual hypersensitivity to radiation therapy in a patient with dyskeratosis congenita syndrome. Oral Oncol. 2004;40(7):758-759. doi:10.1016/j.oraloncology.2004.01.001

12. Komune N, Hara T, Tamae A, et al. A case of dyskeratosis congenita associated with three malignancies. J Oral Maxillofac Surg. 2017;124(4):e239-e242. doi:10.1016/j.oooo.2017.08.001

13. Qureishi A, Lamyman A, Silva P, Cox G. Posterior pharyngeal wall squamous cell carcinoma arising in a patient with dyskeratosis congenita. J Laryngol Otol. 2012;126(12):1299-1301. doi:10.1017/S0022215112001685

14. Kim JH, Kim CS. Squamous cell carcinoma of the tongue in 5-year-old girl with dyskeratosis congenita. Int J Clin Oncol. 2010;15(4):428-432. doi:10.1007/s10147-010-0053-x

15. Qureishi A, Lammyan A, Silva P, Cox G. Posterior pharyngeal wall squamous cell carcinoma arising in a patient with dyskeratosis congenita. J Laryngol Otol. 2012;126(12):1299-1301. doi:10.1017/S0022215112001685

16. Le JM, Kase MT, Morlandt AB. A case of dyskeratosis congenita syndrome. Oral Maxillofac Surg. 2020;6:100-140.

17. Bongiorno M, Rivard S, Hammer D, Kentosh J. Malignant transformation of oral leukoplakia in a patient with dyskeratosis congenita. Oral Maxillofac Surg. 2021;50(9):1041-1045. doi:10.1016/j.ijom.2021.02.027

18. Dharmatman RA, Alter BP. Dyskeratosis congenita. Dermatol Clin. 1995;13(1):33-39.

19. Davidson HR, Connor JM. Dyskeratosis congenita. J Med Genet. 1988;25(12):843-846. doi:10.1136/jmg.25.12.843

20. Mortazavi H, Safi Y, Baharvand M, Jafari S, Anbari F, Rahmani S. Oral white lesions: an updated clinical diagnostic decision tree. Dent J. 2019;7(1):15. doi:10.3390/dj7010015
21. Wald C, Diner H. Dyskeratosis congenita with associated periodontal disease. *Oral Surg Oral Med Oral Pathol*. 1974;37(5):736-744. doi:10.1016/0030-4220(74)90139-x

22. Yavuzyilmaz E, Yamalik N, Yetgin S, Kansu O. Oral-dental findings in dyskeratosis congenita. *J Oral Pathol Med*. 1992;21(6):280-284. doi:10.1111/j.1600-0714.1992.tb01011.x

23. Cannell H. Dyskeratosis congenita. *Br J Oral Surg*. 1971;9:8-20.

24. Iocca O, Sollecito TP, Alawi F, et al. Potentially malignant disorders of the oral cavity and oral dysplasia: a systematic review and meta-analysis of malignant transformation rate by subtype. *Head Neck*. 2020;42(3):539-555. doi:10.1002/hed.26006

25. Savage SA, Dokal I, Armanios M, et al. Dyskeratosis congenita: the first NIH clinical research workshop. *Pediatr Blood Cancer*. 2009;53:520-523.